Literature DB >> 26141627

Demographic Studies from a National Gaucher Disease Screening Program.

D M Gagnon1, E Pergament, B A Fine.   

Abstract

In May 1993, the National Gaucher Foundation initiated a nationwide Gaucher disease screening program in an attempt to promote recognition of the disease and to detect previously undiagnosed individuals. The program was based on self-selection by clinical symptoms of individuals who wanted to be tested for Gaucher disease. Information about symptoms, age, ancestry, gender, and family history was obtained via a self-report screening form completed by 700 individuals. Individuals designated at "high risk" for Gaucher disease were offered beta-glucocerebrosidase enzyme assay testing. Twenty-four of the respondents (3.4%) had Gaucher disease. The most commonly reported symptoms were fatigue (79.4%), bone pain (73.7%), and tendency to bruise (67.8%). The symptoms which showed a statistical difference between the "high risk" and "low risk" groups were liver enlargement (p < 0.005) and unexplained bone fractures (p < 0.03). The mean number of positive symptoms also showed a statistical difference between the groups (4.38 symptoms vs. 3.86 symptoms; p < 0.02). Due to the small sample size, no statistical comparisons were made on the symptomatology of affected vs. unaffected persons, but a descriptive analysis of these two groups is reported.

Entities:  

Year:  1998        PMID: 26141627     DOI: 10.1023/A:1022876631088

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  8 in total

1.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

Authors:  A Zimran; T Gelbart; B Westwood; G A Grabowski; E Beutler
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

2.  Genetic screening for ethnic minorities.

Authors:  M Modell; B Modell
Journal:  BMJ       Date:  1990-06-30

Review 3.  Gaucher disease. Enzymology, genetics, and treatment.

Authors:  G A Grabowski
Journal:  Adv Hum Genet       Date:  1993

Review 4.  The diffusion of new genetic tests for predicting disease.

Authors:  N A Holtzman
Journal:  FASEB J       Date:  1992-07       Impact factor: 5.191

5.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

6.  Enzyme augmentation in moderate to life-threatening Gaucher disease.

Authors:  S Fallet; M E Grace; A Sibille; D S Mendelson; R S Shapiro; G Hermann; G A Grabowski
Journal:  Pediatr Res       Date:  1992-05       Impact factor: 3.756

7.  Enzyme replacement therapy for Gaucher disease.

Authors:  E Beutler; A Kay; A Saven; P Garver; D Thurston; A Dawson; B Rosenbloom
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

8.  Introduction: new technologies for genetic and newborn screening.

Authors:  M R Seashore; C Walsh-Vockley
Journal:  Yale J Biol Med       Date:  1991 Jan-Feb
  8 in total
  1 in total

Review 1.  Rethinking fatigue in Gaucher disease.

Authors:  Y Chen Zion; E Pappadopulos; M Wajnrajch; H Rosenbaum
Journal:  Orphanet J Rare Dis       Date:  2016-04-29       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.